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S U M M A R Y
Background: Q fever caused by the pathogen Coxiella burnetii may have both acute and chronic
manifestations. Although paired sera are not required for the diagnosis of chronic Q fever, monitoring of
antibody titers can be used to examine the course of treatment. Monitoring both phase II and phase I
antibodies may be of limited diagnostic value, but it is a useful means of determining the response to
treatment and possible disease relapses.
Methods: In the current survey we determined IgG and IgM of both phase I and phase II for 35 patients
suffering from chronic Q fever in an attempt to draw conclusions on the kinetics of the antibodies
throughout the course of the disease.
Results: Overall, 33 cases were included in the study. Of the 33 patients, 32 had a good outcome.
Conclusions: Our ﬁndings support the general belief that a long period of serological monitoring is
required for patients with chronic Q fever.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Q fever is a widespread zoonotic infection caused by the
pathogen Coxiella burnetii that has both acute and chronic
manifestations.1 The most frequent manifestations of acute Q
fever include a self-limiting febrile illness, hepatitis, and pneumo-
nia, while chronic Q fever infections are frequently associated with
cardiovascular complications, with endocarditis being the most
common symptom.2 Endocarditis is the most serious and most
frequent clinical presentation of chronic Q fever, and 1– 5% of
patients with acute Q fever and 60–80% of patients with chronic Q
fever develop endocarditis.3 C. burnetii may cause as much as 5% of
all endocarditis cases in some regions and more than half of the
documented cases of endocarditis with negative blood cultures4.
More than 800 cases of endocarditis were reported in various
studies between 1949 and 2005.5
The diagnosis of chronic Q fever is a complex search for
predisposing factors and acute Q fever in patients with an
identiﬁable persistent infection (e.g. endocarditis) (extensively* Corresponding author. Tel.: +30 281 0394743; fax: +30 281 0394740.
E-mail address: annapsa@med.uoc.gr (A. Psaroulaki).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.04.010reviewed in Diagnosis and management of Q fever6 and Raoult7).
The laboratory diagnostic parameters for Q fever are nonspeciﬁc,
thus diagnosis is usually made by serology.
The modiﬁed Duke diagnostic criteria for infective endocarditis
were revised in 2000 to include redeﬁned Q fever serologic
parameters. The revision deﬁned a phase I IgG antibody titer
>1:800, or a single positive blood culture for C. burnetii, as a major
criterion for infective endocarditis. The Duke Endocarditis Service
also advocated the use of transesophageal echocardiograms (TEE)
as the initial diagnostic test of choice in patients categorized as
having possible infective endocarditis, those with suspected
complicated infective endocarditis, and those with suspected
prosthetic valve infective endocarditis. A patient with a phase I IgG
antibody titer >1:800, or a single positive blood culture for C.
burnetii, and one of the following minor criteria would be classiﬁed
as having possible infective endocarditis, thereby warranting the
use of an initial TEE: predisposition, predisposing heart condition
or injection drug use, fever, vascular phenomena, immunological
phenomena, or microbiological evidence.6 However, one must
consider the extensive experience of Raoult’s scientiﬁc group on
the diagnosis of Q fever and take under serious consideration their
belief that a titer of 1:800 should be considered a minor criterionses. Published by Elsevier Ltd. All rights reserved.
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endocarditis in order to avoid a falsely positive diagnosis.7
Past studies conducted in Crete and in Greece have recorded the
endemicity of the pathogen.8–10 The purpose of this study was to
assess the kinetics of antibodies against phase I and II antigens of C.
burnetii during the chronic form of Q fever in an attempt to
highlight the role of antibody kinetics in terms of serological cure
and relapse.
2. Materials and methods
Patients diagnosed with Q fever by immunoﬂuorescence assay
and clinical ﬁndings, from 2001 through 2010, were included in
this study. Clinical and epidemiological data were obtained for
these patients. The physician in charge completed a questionnaire
to obtain data on epidemiological and clinical features. Past
medical history was examined, and patients underwent clinical
cardiovascular examinations and cardiac ultrasonography. The
date when Q fever was diagnosed and the evolution and outcome
of the infection were recorded for each patient. Other infectiousTable 1
Epidemiological data, clinical signs, complications, and therapy used for each of the pa
Patient Age,
years
Date of diagnosis,
month and year
Days between
ﬁrst and last
testing
Major
complication
1 70 February 2007 153 Endocarditis 
2 71 October 2007 944 Vegetation 
3 71 November 2008 723 Stenosis of aortic valve 
4 August 2006 112 
5 55 February 2007 1337 Endocarditis 
6 37 August 2009 308 Respiratory infection 
7 62 June 2008 146 Respiratory infection 
8 41 June 2001 2194 Endocarditis 
9 56 July 2008 180 Respiratory infection 
10 37 February 2009 162 Respiratory infection 
11 45 October 2008 704 Respiratory infection 
12 52 February 2009 349 Respiratory infection 
13 46 September 2010 93 Respiratory infection 
14 59 July 2010 160 Respiratory infection 
15 68 February 2008 348 Respiratory infection 
16 37 September 2010 260 Respiratory infection 
17 25 July 2009 370 Respiratory infection 
18 53 January 2006 186 Respiratory infection 
19 47 May 2006 90 Respiratory infection 
20 75 August 2007 718 Respiratory infection 
21 35 October 2005 294 Pericarditis 
22 72 January 2009 320 Respiratory infection 
23 51 April 2008 504 Endocarditis 
24 26 June 2006 959 Endocarditis 
25 53 April 2004 1456 Endocarditis 
26 63 January 2009 313 Aortic valvulopathy 
27 43 December 2008 280 Respiratory infection 
28 35 January 2008 123 Endocarditis, anterior
cusp rupture
29 28 July 2009 321 Pericarditis 
30 38 September 2008 190 Respiratory infection 
31 32 August 2010 111 Respiratory infection 
32 25 July 2009 351 Respiratory infection 
33 41 July 2006 144 Respiratory infection diseases were excluded based on negative blood cultures and the
lack of serological evidence: Toxoplasma gondii, rubella virus,
cytomegalovirus, HIV, hepatitis B virus, inﬂuenza viruses, parvo-
virus B19, adenovirus, Chlamydia species, and Mycoplasma
pneumoniae. The administration of antibiotics and the duration
of treatment were also recorded.
Serum samples were sent to the Laboratory of Clinical
Bacteriology, Parasitology, Zoonoses and Geographical Medi-
cine (the reference laboratory for Q fever) in Crete and tested
by immunoﬂuorescence for C. burnetii phase I and II antigens
using a commercially available kit (FOCUS Diagnostics,
Cypress, CA, USA), in accordance with the manufacturer’s
instructions. Serum with a phase II IgG titer 1:960 and/or a
phase II IgM titer 1:400 or a positive PCR on a whole blood
sample was predictive of acute Q fever. If the phase I IgG titer
was 1:960, chronic Q fever was suspected. Serological relapse
was deﬁned as a new increase in the phase I antigen-speciﬁc
IgG titer of 1:1024 in two samples after serological cure was
conﬁrmed. Cases not fulﬁlling all the above criteria were
excluded.tients included in the study
Surgery Treatment Final outcome
Replacement of
aortic valve
Cephalosporin + tetracycline Survived
Doxycycline + hydroxychloroquine Survived
Replacement Doxycycline + hydroxychloroquine Survived
Doxycycline + hydroxychloroquine Survived
Replacement of
aortic valve,
autologous graft
of pneumonic valve
Doxycycline + quinolones,
then doxycycline
+ hydroxychloroquine
Survived
Doxycycline + hydroxychloroquine Survived
Doxycycline + hydroxychloroquine Survived
Doxycycline + rifampin Survived
Survived
Doxycycline + hydroxychloroquine Survived
Doxycycline + hydroxychloroquine Survived
Doxycycline + hydroxychloroquine Survived
Doxycycline Survived
Doxycycline Survived
Doxycycline + hydroxychloroquine Survived
Doxycycline Survived
Doxycycline + hydroxychloroquine Survived
Doxycycline + hydroxychloroquine Survived
Doxycycline Survived
Doxycycline + hydroxychloroquine Survived
Doxycycline + clarithromycin
+ ciproﬂoxacin
Survived
Doxycycline Survived
Four surgeries with
replacement
of valves
Doxycycline + hydroxychloroquine Died
Replacement of
aortic valve
Doxycycline + hydroxychloroquine Survived
Replacement of
aortic valve
Doxycycline + quinolones,
then doxycycline
+ chloramphenicol, then doxycycline
+ hydroxychloroquine
Survived
Replacement of
aortic valve
Doxycycline + hydroxychloroquine Survived
Doxycycline Survived
Replacement of
mitral valve
Doxycycline + hydroxychloroquine Survived
Doxycycline + hydroxychloroquine Survived
Doxycycline Survived
Doxycycline + hydroxychloroquine Survived
Doxycycline + hydroxychloroquine Survived
Doxycycline + hydroxychloroquine Survived
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software; the level of signiﬁcance was set at p < 0.05.
3. Results
3.1. Patients
From 2001 through 2010, a total of 1158 cases of C. burnetii
infection were diagnosed in Crete. Overall, 33 cases were included
in the study. The diagnosis was made during the ﬁrst trimester of
the year for seven patients, during the second trimester for six
patients, during the third trimester for 13 patients, and during the
fourth trimester for ﬁve patients. Twenty-two patients received
doxycycline with hydroxychloroquine (the recommended therapy
for Q fever), while the remaining patients (n = 11) received a
different treatment. The duration of treatment ranged from 5 to 48
months, and treatment was stopped when IgG phase I titers fell to
<1:120. Eight (24%) patients presented endocarditis, two (6%)
pericarditis, one (3%) stenosis of the aortic valve, and one (3%)
aortic valvulopathy, while the initially diagnosed respiratory
infection did not progress to any other complication for the rest
of the patients (n = 21, 64%). Surgery was needed in eight patients.Figure 1. (A) Plot of IgG/IgM fraction of phase I antibodies against time; the y axis is sca
time; the y axis is scaled on a logarithmic basis. (C) Plot of IgG/IgM fraction of phase II an
logarithmic basis. (D) Demonstration of the fraction phase II/phase I antibodies against t
the equality of phase II and phase I antibody titers. (E) Plot of the distribution of titers o
conﬁdence intervals and the middle curve represents the mean. Circles represent the anti
each titer from the extreme curves. (F) Plot of the distribution of titers of IgG phase II 
intervals and the middle curve represents the mean. Circles represent the antibody titers
from the extreme curves. (G) Plot of the distribution of titers of IgG phase II and phaseOf the 33 patients, 32 were treated effectively. The data obtained
are summarized in Table 1.
3.2. Comparison of patient data
The median titer for IgG phase I antibodies was 512 (range 0–
65,536) and for IgG phase II antibodies was 2048 (range 0–
524,288). Phase I and II IgG antibodies remained detectable for the
entire study period in most cases (31 of 35 patients in our study).
Eight patients had serological relapse.
In an attempt to identify a possible antibody kinetic pattern
among IgM antibodies, the fraction of IgG/IgM antibodies was
plotted over time. The way the fraction expanded over time was
similar for both phase II and phase I antibodies, although in the
case of phase I antibodies the corresponding line was steeper. This
might be due to the fact that during the initial stages of the
infection, some high titers of IgM phase I antibodies may be
revealed, which, however, tend to zero with time. With regard to
phase II antibodies, the fraction was seldom below one (IgM > IgG)
(Figure 1, A and B). In general, the fraction of IgG/IgM phase II
antibodies against the corresponding fraction for phase I was
generally above one (Figure 1C).led on a logarithmic basis. (B) Plot of IgG/IgM fraction of phase II antibodies against
tibodies against the IgG/IgM fraction of phase I antibodies; both axes are scaled on a
ime; the y axis is a logarithmic one and the horizontal line from number 1 indicates
f IgG phase I antibodies against time; the top and bottom curves represent the 95%
body titers; the vertical lines beginning from each titer correspond to the distance of
antibodies against time; the top and bottom curves represent the 95% conﬁdence
; the vertical lines beginning from each titer correspond to the distance of each titer
 I antibodies against time; circles represent the antibody titers.
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compared to phase I titers, except from the early months of
infection where there were some cases with reverse titers. Over
time the fraction phase II/phase I tended towards one, probably
due to the trend to equalize (Figure 1D).
Nevertheless, the pattern of variation of phase II and phase I IgG
antibodies remained similar over time (Figure 1, E–G).
4. Discussion
The laboratory diagnosis of Q fever relies mainly on serological
examination and PCR. During chronic Q fever, very high titers of
anti-phase I IgG antibodies are detected.1 In the current study, both
phase II and phase I IgG antibodies remained at high levels during
the course of the disease. The titers of IgM were variable, in some
cases very high and in some very low. IgM antibodies remained at
low titers throughout the follow-up of the patients. This is
consistent with the fact that the signiﬁcance of IgM antibodies in
the follow-up of chronic Q fever is rather limited. However, there
are patients with documented endocarditis with lower antibody
titers (Million et al., 2010). Echocardiography is necessary when a
valve lesion is known or suspected, and PET scanning for the
diagnosis of a vascular infection appears to be essential.11
The prognosis of chronic Q fever has improved dramatically
over the course of just a few years. The mortality rate was 37% in a
report of 76 patients in 1987,12 it was only 15% in a more recent
report of 116 patients between 1997 and 2000,13 and it has now
dropped to approximately 5%.4 Studies have suggested that
combination treatment for 18 months should be the recommended
treatment for Q fever endocarditis, except in patients with
prosthetic valves or for special cases with a poor clinical or
serological evolution (Million et al., 2010). This duration should be
extended only in the absence of a favorable serological outcome.
Serological monitoring for at least 5 years is appropriate, given the
risk of relapse. Patients with at least a four-fold decrease in the
phase I antigen-speciﬁc IgG titer at 1 year have better outcomes,
which conﬁrms the prognostic value of serological monitoring to
assess the efﬁcacy of treatment (Million et al., 2010).
The patterns in which phase I and phase II antibodies changed
over time were similar. Overall, phase II antibodies tended to
remain at high titers, however no statistically signiﬁcant
difference (p < 0.05) was calculated among the phase I and
phase II IgG titers during the course of the study. The serum levels
of antibodies decreased very slowly. Furthermore, IgG phase I
antibodies seemed to initiate from a lower point compared tophase II antibodies. IgM antibodies, when present, disappear ﬁrst,
however IgG antibodies remain detectable for years. The antibody
titers fall slowly during treatment and, while not protective, they
predict the progression of the disease. A decrease of more than
two dilutions of titers of these antibodies after 1 year of treatment
is considered to be a favorable response.14 In any case, proper
management of Q fever is necessary to prevent possible
subsequent complications.
In conclusion, although paired sera are not required for the
diagnosis of chronic Q fever, the antibody titers can be used to
monitor the course of treatment. Thus, evaluating the ratio of
phase II against phase I antibodies might be of limited diagnostic
value, but it is a useful means of monitoring the response to
treatment and possible disease relapses. Our ﬁndings are consis-
tent with former studies, which have stated that a long period of
serological monitoring of patients with chronic Q fever is required.
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